Alector ALEC 深 滬
交易中 09-05 11:43:13 美东时间
3.02
+0.200
+7.09%
華盛通- 最 高3.04
- 今 開2.83
- 成交量 75.70万股
- 最 低 2.83
- 昨 收 2.82
- 總市值 3.02亿
- 52周最高 6.37
- 市盈率 靜 --
- 換手率 0.76%
- 52周最低 0.87
- 委 比 42.45%
- 總股本 9999.26万
- 歷史最高 43.32
- 量 比 2.28
- 振 幅 7.45%
- 歷史最低 0.87
- 每 手 1
- 風險率 1.49%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Alector to Participate in Upcoming Healthcare Conferences
Alector, Inc. announced that its management will participate in three upcoming investor conferences in New York: the Cantor Global Healthcare Conference 2025 on September 4, the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, and the H.C. Wainwright 27th Annual Global Investment Conference on September 9. Webcasts of the presentations will be available on Alector’s website, with replays accessible for 90 days. Alector focu...
08-28 12:00
Alector Raises FY2025 Sales Guidance from $5.000M-$15.000M to $13.000M-$18.000M vs $12.114M Est
Alector (NASDAQ:ALEC) raises FY2025 sales outlook from $5.000 million-$15.000 million to $13.000 million-$18.000 million vs $12.114 million estimate.
08-08 04:48
Here are the major earnings after the close Thursday
Major earnings expected after the bell on Thursday include: Block (XYZ) Gilead Sciences (GILD) Twilio (TWLO) The Trade Desk (TTD) Main Street Capital Corporation (MAIN) Other earnings slated for rele...
08-07 22:00
Alector Reports Second Quarter 2025 Financial Results and Provides Business Update
Alector reported Q2 2025 financial results and updates on its pipeline, including the pivotal INFRONT-3 Phase 3 trial of latozinemab for FTD-GRN, expected to report top-line data by mid-Q4 2025. The Phase 2 PROGRESS-AD trial of AL101 in early Alzheimer's disease is ongoing, with completion expected in 2026. The company also highlighted progress in its Brain Carrier programs, including anti-amyloid beta, GCase enzyme replacement therapy, and anti-...
08-07 20:05
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call
<p>Alector, a clinical-stage biotech company focused on neurodegenerative diseases, announced a conference call on August 7, 2025, at 4:30 p.m. ET, to discuss Q2 2025 results and mid-year updates. A press release will be issued prior to the call, and a webcast will be available under the investor relations section of Alector’s website. Participants can register online to join by phone. Ryan Darby, MD, will discuss the unmet need in frontotemporal...
07-31 20:05
Alector upgraded at Mizuho on high risk/higher-reward
Alector (NASDAQ:ALEC) was surging after Mizuho Securities upgraded the biotechnology stock, citing "high risk/higher-reward bet". Shares were +9.09% during morning trade to $1.92. "Investing in the ne...
07-28 22:46
Mizuho Upgrades Alector to Outperform, Raises Price Target to $3.5
Mizuho analyst Graig Suvannavejh upgrades Alector (NASDAQ:ALEC) from Neutral to Outperform and raises the price target from $2.5 to $3.5.
07-28 19:08
Kyverna Therapeutics appoints Marc Grasso as CFO
Kyverna Therapeutics (NASDAQ:KYTX) announced on Monday the appointment of Marc Grasso as its chief financial officer (CFO), effective today. Most recently, Grasso served as CFO of Alector, a clinical...
06-30 21:32
Alector appoints Neil Berkley as interim CFO
Alector (NASDAQ:ALEC) announced on Friday that Marc Grasso, chief financial officer (CFO) of the company, will conclude his tenure effective June 20, 2025, to pursue other opportunities. Neil Berkley,...
06-14 04:15
